Clear Scientific

Executive Summary

Clear Scientific is a San Diego-based biopharmaceutical company developing novel small-molecule sequestrant drugs designed to bind, inactivate, and clear harmful substances from the bloodstream and gastrointestinal tract. Founded in 2017, the company focuses on life-threatening conditions caused by excess toxins, starting with overdose reversal agents. Its proprietary platform offers potential for treating metabolic and neurodegenerative disorders where accumulation of pathological compounds drives disease progression. By leveraging a differentiated mechanism that directly removes target molecules, Clear Scientific aims to address urgent unmet needs in acute and chronic indications, positioning itself as a pioneer in the sequestrant drug space. The company has not yet disclosed specific pipeline candidates or clinical timelines, but its technology has attracted attention from the biopharma community. Clear Scientific likely requires additional financing or partnerships to advance lead programs into clinical testing. Potential near-term catalysts include preclinical proof-of-concept data, engagement with regulatory agencies, or formation of strategic alliances. While still early-stage, the platform's versatility suggests multiple applications, though valuation remains uncertain given limited public information. The company is privately held and has not reported significant funding rounds or clinical milestones, indicating a need for updated disclosures.

Upcoming Catalysts (preview)

• TBDPreclinical Data for Lead Overdose Reversal Candidate60% success
• Q2 2027Series A Funding or Strategic Partnership Announcement50% success
• Q4 2027IND Filing for First-in-Class Sequestrant Drug30% success